These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 33118992)

  • 1. Changes in the uptake of screening for prostate cancer with prostate-specific antigen in Ontario between 2003 to 2012.
    Watson L
    Can Oncol Nurs J; 2020; 30(2):125-132. PubMed ID: 33118992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen utilization in Ontario: extent of testing in patients with and without cancer.
    Bunting PS; Chong N; Holowaty EJ; Goel V
    Clin Biochem; 1998 Aug; 31(6):501-11. PubMed ID: 9740973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen (PSA) screening rates and factors associated with screening in Eastern Canadian men: Findings from cross-sectional survey data.
    Tchir D; Farag M; Szafron M
    Can Urol Assoc J; 2020 Jul; 14(7):E319-E327. PubMed ID: 32017690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Related to Prostate-Specific Antigen-Based Prostate Cancer Screening in Primary Care: Retrospective Cohort Study of 120,587 French Men Over the Age of 50 Years.
    Rat C; Schmeltz H; Rocher S; Nanin F; Gaultier A; Nguyen JM
    JMIR Public Health Surveill; 2018 Oct; 4(4):e10352. PubMed ID: 30355559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of Prostate-Specific Antigen (PSA) Testing in the US Population: Results from a National Cross-Sectional Survey.
    Johnson JA; Moser RP; Ellison GL; Martin DN
    J Community Health; 2021 Apr; 46(2):389-398. PubMed ID: 33064229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
    Bunting PS; Goel V; Williams JI; Iscoe NA
    CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ever and Annual Use of Prostate Cancer Screening in African American Men.
    Halbert CH; Gattoni-Celli S; Savage S; Prasad SM; Kittles R; Briggs V; Delmoor E; Rice LJ; Jefferson M; Johnson JC
    Am J Mens Health; 2017 Jan; 11(1):99-107. PubMed ID: 26240090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
    Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
    Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opportunistic prostate cancer screening: A population-based analysis.
    Matti B; Zargar-Shoshtari K
    Urol Oncol; 2020 May; 38(5):393-400. PubMed ID: 31952998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities.
    Williams N; Hughes LJ; Turner EL; Donovan JL; Hamdy FC; Neal DE; Martin RM; Metcalfe C
    BJU Int; 2011 Nov; 108(9):1402-8. PubMed ID: 21481132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
    Dyche DJ; Ness J; West M; Allareddy V; Konety BR
    J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shared decision making in prostate-specific antigen testing with men older than 70 years.
    Li J; Berkowitz Z; Richards TB; Richardson LC
    J Am Board Fam Med; 2013; 26(4):401-8. PubMed ID: 23833155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners.
    Drummond FJ; Carsin AE; Sharp L; Comber H
    BMC Fam Pract; 2009 Jan; 10():3. PubMed ID: 19138385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlates of prostate-specific antigen testing in a large multiethnic cohort.
    Haque R; Van Den Eeden SK; Jacobsen SJ; Caan B; Avila CC; Slezak J; Sternfeld B; Loo RK; Quinn VP
    Am J Manag Care; 2009 Nov; 15(11):793-9. PubMed ID: 19895183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring patient perceptions of PSA screening for prostate cancer: risks, effectiveness, and importance.
    Smith SD; Birtwhistle R
    Can Fam Physician; 2012 Sep; 58(9):e502-7. PubMed ID: 22972741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia.
    Meigs JB; Barry MJ; Giovannucci E; Rimm EB; Stampfer MJ; Kawachi I
    Am J Med; 1998 Jun; 104(6):517-25. PubMed ID: 9674713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-screening Discussions and Prostate-Specific Antigen Testing for Prostate Cancer Screening.
    Li J; Zhao G; Hall IJ
    Am J Prev Med; 2015 Aug; 49(2):259-63. PubMed ID: 25997905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.